Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones

by

in

Axsome Therapeutics Inc (NASDAQ:AXSM) reported fourth-quarter 2023 revenues of $71.53 million, up from $24.37 million a year ago, beating the consensus of $67.69 million.

Auvelity (oral antidepressant) net product sales were $49 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch. 

Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase.

Sunosi (sleep disorder) net product revenues were $22.5 million and $74.8 million for the fourth quarter and full year of 2023, representing 17% and 67% Y/Y growth, respectively.

Also Read: 

Full story available on Benzinga.com


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *